Clinical trial • Phase IV • Other

Levonorgestrel for Post-medical abortion contraception

Phase IV trial of Levonorgestrel for Post-medical abortion contraception.

Overview

Trial Therapeutic Area
Other
Trial Disease
Post-medical abortion contraception
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
28-09-2024
First CTIS Authorization Date
09-10-2024

Trial design

Randomised, open-label, immediate insertion of intrauterine contraception versus delayed insertion at 2-4 weeks post abortion-controlled Phase IV trial across 7 sites in Sweden.

Randomised
Yes
Open Label
Yes
Comparator
Immediate insertion of intrauterine contraception versus delayed insertion at 2-4 weeks post abortion
Target Sample Size
720
Trial Duration For Participant
365

Eligibility

Recruits 720 Vulnerable population selected. Exclusion criterion: "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents..

Vulnerable Population
Vulnerable population selected. Exclusion criterion: "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents.

Inclusion criteria

  • {"criterion_text":"- above 18 years old\n- eligible for medical abortion\n- opting for post abortion Intrauterine contraception\n- able and willing to comply with planned follow up"}

Exclusion criteria

  • {"criterion_text":"- contraindication for medical abortion\n- contraindication for intrauterine contraception (contraindications may be present for LNG- IUSs but the woman may still choose a Cu-IUD and thereby enter the study),\n- inability to give informed consent.\n- Septic abortion"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The proportion of women in each group (immediate or delayed) using intrauterine contraception as contraception at 6 months post abortion","definition_or_measurement_approach":"Proportion of women in each group using intrauterine contraception at 6 months post abortion (measured as use of IUC at 6 months post abortion)."}

Secondary endpoints

  • {"endpoint_text":"- Use of IUC at 3, 6 and 12 months post insertion evaluated by telephone or e-mail follow-up (continued use/voluntary discontinued use, involuntary discontinued use including expulsions etc) reasons for discontinuation will be recorded and subsequent use of other contraceptive methods will be noted)","definition_or_measurement_approach":"Measured by telephone or e-mail follow-up at 3, 6 and 12 months; continued use, voluntary/involuntary discontinuation, reasons and subsequent contraceptive use recorded."}
  • {"endpoint_text":"- Difference in the proportion of women who successfully have the IUC inserted (success versus failure),","definition_or_measurement_approach":"Proportion of successful versus failed insertions recorded."}
  • {"endpoint_text":"- Ease of insertion according to health care provider (judged as very easy, easy, moderately, or very difficult)","definition_or_measurement_approach":"Provider-judged ease of insertion categorized as very easy, easy, moderately, or very difficult."}
  • {"endpoint_text":"- pain at time of insertion (women will indicate the pain before insertion, at placement of tenaculum, sound and IUC by putting a vertical mark on a 10 cm long horizontal line with a Visual Analogue Scale (VAS) from 0, indicating no pain to 10 indicating worst imaginable pain. Result will be noted in millimeters and entered into case report forms).","definition_or_measurement_approach":"Pain measured using a 10 cm Visual Analogue Scale (VAS); marks converted to millimetres and entered into case report forms."}
  • {"endpoint_text":"- Post-abortion bleeding (number of days of fresh bleeding and spotting after the abortion)","definition_or_measurement_approach":"Number of days of fresh bleeding and spotting recorded post-abortion."}
  • {"endpoint_text":"- Reasons for non-attempted insertion of IUC (change of mind, heavy bleeding, not coming for insertion, staff being unavailable etc),","definition_or_measurement_approach":"Reasons for non-attempted insertion documented (e.g., change of mind, heavy bleeding, no show, staff unavailable)."}
  • {"endpoint_text":"- Pregnancies occurring during the 6 and 12 month follow-up (planned and unplanned, wanted and unwanted, pregnancy outcomes- ectopic, miscarriage, abortion, molar, kept pregnancy),","definition_or_measurement_approach":"Pregnancies during 6 and 12 month follow-up recorded with outcomes (ectopic, miscarriage, abortion, molar, continued pregnancy)."}
  • {"endpoint_text":"- Acceptability of immediate and delayed insertion of IUC by asking women if they would recommend the procedure to a friend (yes/no, asked at the time of insertion and at the 3 and 6 month follow up),","definition_or_measurement_approach":"Acceptability assessed by asking participants yes/no if they would recommend the procedure at insertion and at 3- and 6-month follow-ups."}
  • {"endpoint_text":"- Acceptability of IUC as post abortion contraception- evaluated as above,","definition_or_measurement_approach":"Acceptability of IUC as post-abortion contraception evaluated similarly (participant responses recorded)."}
  • {"endpoint_text":"- Expulsion rate during 12 months following insertion in both groups evaluated by telephone follow up at 3, 6 and 12 months post abortion (complete, partial or no expulsion. The exact day of expulsion will be noted to determine the risk of expulsion as a function of time post insertion),","definition_or_measurement_approach":"Expulsion rate assessed by telephone follow-up at 3, 6 and 12 months; complete/partial/no expulsion recorded and exact day of expulsion noted."}
  • {"endpoint_text":"- Complications (adverse events (AE) and serious AE) bleeding requiring any treatment, uterine perforations and cervical tears, infection requiring treatment with antibiotics, hospitalization for any reason, surgical procedures due to heavy bleeding, incomplete abortions, prolonged bleeding or patient request,","definition_or_measurement_approach":"Complications and adverse events (including bleeding requiring treatment, perforations, tears, infections requiring antibiotics, hospitalizations, surgical procedures) recorded."}
  • {"endpoint_text":"- The proportion of surgical procedures in total and for each study site (type of procedure, reasons therefore- infection, retained products of conception, prolonged bleeding etc).","definition_or_measurement_approach":"Proportion and type of surgical procedures recorded overall and by site, with reasons (infection, retained products, prolonged bleeding, etc.)."}

Recruitment

Planned Sample Size
720
Recruitment Window Months
65
Consent Approach
Informed consent to be obtained from participants; inclusion restricted to adults ("above 18 years old"). Exclusion includes "inability to give informed consent." Subject information and informed consent form documents are listed in the trial documents. No assent process or languages are specified in the available data.

Geography

Total Number Of Sites
7
Total Number Of Participants
720

Sweden

Earliest CTIS Part Ii Submission Date
28-09-2024
Latest Decision Or Authorization Date
09-10-2024
Processing Time Days
11
Number Of Sites
7
Number Of Participants
720

Sites

Site Name
Uppsala University Hospital
Department Name
dept of Ob/gyn
Principal Investigator Name
Emma Håstad
Principal Investigator Email
emma.hastad@akademiska.se
Contact Person Name
Emma Håstad
Contact Person Email
emma.hastad@akademiska.se
Site Name
Danderyds Sjukhus AB
Department Name
dept of Ob/gyn
Principal Investigator Name
Helena Kopp Kallner
Principal Investigator Email
helena.kopp-kallner@ki.se
Contact Person Name
Helena Kopp Kallner
Contact Person Email
helena.kopp-kallner@ki.se
Site Name
Region Dalarna
Department Name
dept of Ob/gyn
Principal Investigator Name
Sara Hogmark
Principal Investigator Email
sara.hogmark@regiondalarna.se
Contact Person Name
Sara Hogmark
Contact Person Email
sara.hogmark@regiondalarna.se
Site Name
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Department Name
dept of Ob/gyn
Principal Investigator Name
Helena Hognert
Principal Investigator Email
helena.hognert@vgregion.se
Contact Person Name
Helena Hognert
Contact Person Email
helena.hognert@vgregion.se
Site Name
Karolinska University Hospital
Department Name
dept of Ob/gyn
Principal Investigator Name
Kristina Gemzell
Principal Investigator Email
kristina.gemzell@ki.se
Contact Person Name
Kristina Gemzell
Contact Person Email
kristina.gemzell@ki.se
Site Name
Soedersjukhuset AB
Department Name
dept of Ob/gyn
Principal Investigator Name
Cecilia Berger
Principal Investigator Email
cecilia.berger@regionstockholm.se
Contact Person Name
Cecilia Berger
Site Name
Lund University Hospital
Department Name
dept of Ob/gyn
Principal Investigator Name
Pia Teleman
Principal Investigator Email
pia.teleman@skane.se
Contact Person Name
Pia Teleman
Contact Person Email
pia.teleman@skane.se

Sponsor

Primary sponsor

Full Name
Karolinska Institutet
Organisation Type
Educational Institution
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
Mirena 20 mikrogram/24 timmar intrauterint inlägg
Active Substance
Levonorgestrel
Modality
Small molecule
Routes Of Administration
INTRAUTERINE USE
Route
INTRAUTERINE USE
Authorisation Status
Authorised
Starting Dose
Mirena 20 mikrogram/24 timmar intrauterint inlägg
Frequency
Single insertion; duration up to 96 months
Investigational Product Name
Kyleena® 19,5 mg, intrauterint inlägg
Active Substance
Levonorgestrel
Modality
Small molecule
Routes Of Administration
INTRAUTERINE USE
Route
INTRAUTERINE USE
Authorisation Status
Authorised
Starting Dose
Kyleena® 19,5 mg, intrauterint inlägg
Frequency
Single insertion; duration up to 60 months
Investigational Product Name
Jaydess 13,5 mg, intrauterint inlägg
Active Substance
Levonorgestrel
Modality
Small molecule
Routes Of Administration
INTRAUTERINE USE
Route
INTRAUTERINE USE
Authorisation Status
Authorised
Starting Dose
Jaydess 13,5 mg, intrauterint inlägg
Frequency
Single insertion; duration up to 36 months

Related trials

Other published trials that may interest you.